A Modgil

B Dong

C Zhang

CA van Kesteren

CF Tsai

CY Tsai

DJ Campbell

E Gava

E Shen

FD Marques

I Manabe

IG Poornima

J Mori

J Zhong

JT Ortiz-Pérez

K Yamada

LT McCollum

PP Hao

Q Ali

RA Santos

S Ares-Carrasco

S Epelman

S Ohtani

S Sarkar

S Tesanovic

SV Pinheiro

TM Murça

V Gross

VB Patel

VP Singh

Y Ti

YX Zhao

Z Pei

Z Su

Scientific Reports

AbstractWe recently found that overexpression of angiotensin (Ang)-converting enzyme 2, which metabolizes Ang-II to Ang-(1–7) and Ang-I to Ang-(1–9), may improve left ventricular remodeling in diabetic cardiomyopathy. Here we aimed to test whether chronic infusion of Ang-(1–7) can dose-dependently ameliorate left ventricular remodeling and function in a rat model of diabetic cardiomyopathy and whether the combination of Ang-(1–7) and Ang-converting enzyme inhibition may be superior to single therapy. Our results showed that Ang-(1–7) treatment dose-dependently ameliorated left ventricular remodeling and dysfunction in diabetic rats by attenuating myocardial fibrosis, myocardial hypertrophy and myocyte apoptosis via both the Mas receptor and angiotensin II type 2 receptor. Furthermore, combining Ang-(1–7) with perindopril provided additional cardioprotection relative to single therapy. Ang-(1–7) administration provides a novel and promising approach for treatment of diabetic cardiomyopathy.</jats:p

Panpan Hao

Jianmin Yang

Yanping Liu

Mingxiang Zhang

Kai Zhang

Fei Gao

Yuguo Chen

Cheng Zhang

Yun Zhang

Crossref

Combination of angiotensin-(1–7) with perindopril is better than single therapy in ameliorating diabetic cardiomyopathy

Combination of angiotensin-(1–7) with perindopril is better than single therapy in ameliorating diabetic cardiomyopathy

Abstract

Similar works

Full text

Available Versions

Crossref